Cinrebafusp alfa

希比芙普α

Report date: 2024/12/19 13:40:41

Base Information

Drug NameCinrebafusp alfa

Drug Alias NamePRS-343

ClassificationBiologics > Protein drugs > Recombinant protein > Fusion proteinBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody

Mechanisms of ActionTumor necrosis factor receptor superfamily member 9 agonistsReceptor protein-tyrosine kinase erbB-2 modulators

TargetsTumor necrosis factor receptor superfamily member 9Receptor protein-tyrosine kinase erbB-2

Therapy Area/IndicationsSolid tumoursUrinary Bladder NeoplasmsStomach Neoplasms +[4]

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited StatesSouth Korea

CombinationsNo

Global Highest StatusPhase 2 Clinical

Highest Status in ChinaN/A

Originator CompaniesPieris Pharmaceuticals

China Registration ClassN/A

Develop Information

Active CompaniesPieris Pharmaceuticals Inc

Inactive CompaniesN/A

Active IndicationsSolid tumoursUrinary Bladder NeoplasmsStomach Neoplasms +[4]

Inactive IndicationsN/A

Other Information

ATC CodeN/A